New pill combo aims to stall advanced breast cancer after chemo
NCT ID NCT07371910
First seen Jan 29, 2026 · Last updated May 21, 2026 · Updated 17 times
Summary
This phase 3 study tests whether a combination of two oral targeted drugs (fluorizoparib and apatinib) can keep a specific type of advanced breast cancer from growing longer than standard chemotherapy. The trial includes 200 women with HRD-positive, HER2-negative breast cancer. After initial chemotherapy, some patients switch to the targeted pills as long-term maintenance therapy, while others continue standard chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510030, China
Conditions
Explore the condition pages connected to this study.